Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current developments in extracellular-regulated protein kinase (ERK1/2) inhibitors
Yuzhen Niu, Hong‐Fang Ji
Drug Discovery Today (2022) Vol. 27, Iss. 5, pp. 1464-1473
Closed Access | Times Cited: 13

Showing 13 citing articles:

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Yanlin Song, Zhenfei Bi, Yu Liu, et al.
Genes & Diseases (2022) Vol. 10, Iss. 1, pp. 76-88
Open Access | Times Cited: 115
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
Kun Pang, Wei Wang, Jiaxin Qin, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 67
Targeting the RAS upstream and downstream signaling pathway for Cancer treatment
Md. Arafat Hossain
European Journal of Pharmacology (2024) Vol. 979, pp. 176727-176727
Closed Access | Times Cited: 15
Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors
Leilei Fu, Siwei Chen, Gu He, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 13561-13573
Closed Access | Times Cited: 29
Combination Therapy with Resveratrol and Celastrol Using Folic Acid‐Functionalized Exosomes Enhances the Therapeutic Efficacy of Sepsis
Xue Zheng, Yujie Xing, Ke Sun, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 29
Open Access | Times Cited: 18
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Computational study on the mechanism of small molecules inhibiting NLRP3 with ensemble docking and molecular dynamic simulations
P. Qin, Yuzhen Niu, Jizheng Duan, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 6, pp. 777-778
Open Access | Times Cited: 1
Proteomic analysis of mouse liver lesions at all three stages of Echinococcus granulosus infection
Nan Jiang, Chen Yang, Teng Li, et al.
PLoS neglected tropical diseases (2024) Vol. 18, Iss. 12, pp. e0012659-e0012659
Open Access | Times Cited: 1
Anti-arthritic effects of dibenzylbutane lignans from Litsea cubeba through suppression of MEK-ERK-p90RSK signalling
Yuanyuan Dai, Kunmiao Feng, Ping Han, et al.
Research Square (Research Square) (2024)
Open Access
Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells
Chen Fu, Zongcai Liu, Taixue An, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2023) Vol. 1867, Iss. 10, pp. 130439-130439
Closed Access | Times Cited: 1
Machine learning-integrated and fingerprint-based similarity search against immuno oncology library for identification of novel ERK2 inhibitors
Vikramsinh Sardarsinh Suryawanshi, Surbhi Pravin Pawar, Mahima Sudhir Kolpe, et al.
Structural Chemistry (2024)
Closed Access
Page 1

Scroll to top